Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer

British Journal of Cancer

Volumn 103, Issue 12, 2010, Pages 1822-1830

  Araki, K ^a,b   Yamashita, T ^a,b   Reddy, N ^a   Wang, H ^a   Abuzeid, ^a   Khan, K ^a   O'Malley Jr , B W ^a   Li, D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

adenovirus; chemoresistance; DNA double strand breaks; DNA repair; NBS1; targeted gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MRE11 PROTEIN; NIBRIN; RAD50 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER MODEL; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG PROTEIN BINDING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSDUCTION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; LIVER; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS;

EID: 78649994787     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605980     Document Type: Article

References (43)

1. Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, Jungreis D, Carney J, O'Malley Jr BW, Li D (2009) Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin Invest 119: 1974-1985
2. Akiyama M, Thorne S, Kirn D, Roelvink PW, Einfeld DA, King CR, Wickham TJ (2004) Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol Ther 9: 218-230
3. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM (2005) Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 280: 18771-18781
4. Araki K, Ahmad SM, Li G, Bray Jr DA, Saito K, Wang D, Wirtz U, Sreedharan S, O'Malley Jr BW, Li D (2008) Retinoblastoma RB94 enhances radiation treatment of head and neck squamous cell carcinoma. Clin Cancer Res 14: 3514-3519
5. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U (1995) Control of IkB-a proteolysis by site-specific, signal-induced phosphorylation. Science 267: 1485-1488
6. Chen YC, Chiang HY, Yang HM, Chen PM, Chang SY, Teng SC, Vanhaesebroeck B, Wu KJ (2008) Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. J Mol Med 86: 401-412
7. Chu G (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790
8. Czornak K, Chughtai S, Chrzanowska KH (2008) Mystery of DNA repair: The role of the MRN complex and ATM kinase in DNA damage repair. J Appl Genet 49: 383-396
9. Dellacono FR, Spiro J, Eisma R, Kreutzer D (1997) Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am J Surg 174: 540-544
10. Doukas J, Hoganson DK, Ong M, Ying W, Lacey DL, Baird A, Pierce GF, Sosnowski BA (1999) Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J 13: 1459-1466
11. Drummond JT, Anthoney A, Brown R, Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648
12. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886 (Pubitemid 26374423)
13. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, Curiel DT (1997) Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57: 1447-1451
14. Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A, Aukerman SL, Pierce GF (1999) Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res 59: 2608-2614
15. Gupta V, Wang W, Sosnowski S, Hofman FM, Chen TC (2006) Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells. Neurosurg Focus 20: E26
16. Habraken Y, Piette J (2006) NF-kappaB activation by double-strand breaks. Biochem Pharmacol 72: 1132-1141
17. Janssens S, Tschopp J (2006) Signals from within: The DNA-damageinduced NF-kappaB response. Cell Death Differ 13: 773-784
18. Jiang BH, Liu LZ (2008) PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158
19. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43
20. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584
21. Kleeff J, Fukahi K, Lopez ME, Friess H, Büchler MW, Sosnowski BA, Korc M (2002) Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther 9: 522-532
22. Kobayashi J, Antoccia A, Tauchi H, Matsuura S, Komatsu K (2004) NBS1 and its functional role in the DNA damage response. DNA Repair 3: 855-861
23. Li B, Li YY, Tsao SW, Cheung ALM (2009) Targeting NF-kB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther 8: 2635-2644
24. Li D, Day KV, Yu S, Shi G, Liu S, Guo M, Xu Y, Sreedharan S, O'Malley Jr BW (2002) The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer. Cancer Res 62: 4637-4644
25. Li D, Duan L, Freimuth P, O'Malley Jr BW (1999) Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 5: 4175-4181
26. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 14: 1291-1295
27. O'Malley Jr BW, Li D, Carney J, Rhee J, Suntharalingam M (2003) Molecular disruption of the MRN(95) complex induces radiation sensitivity in head and neck cancer. Laryngoscope 113: 1588-1594
28. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542
29. Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF, Aukerman SL (2000) Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther 11: 191-204
30. Qin M, Escuadro B, Sharma S, Batra RK (2005) Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells. Am J Respir Cell Mol Biol 32: 211-217
31. Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piché A, Pierce GF, Alvarez RD, Siegal GP, Douglas JT, Curiel DT (1998) Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 4: 2455-2461
32. Riedel F, Götte K, Bergler W, Rojas W, Hörmann K (2000) Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 22: 183-189
33. Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT (1997) Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther 4: 1387-1392
34. Sagan D, Eckardt-Schupp F, Eichholtz-Wirth H (2008) Reduced expression of SRC family kinases decreases PI3K activity in NBS1-/- lymphoblasts. Biochem Biophys Res Commun 377: 181-186
35. Saito K, Khan K, Sosnowski B, Li D, O'Malley BW (2009) Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy. Laryngoscope 119: 665-674
36. Sewell DA, Li D, Duan L, Westra WH, O'Malley Jr BW (1997) Safety of in vivo adenovirus-mediated thymidine kinase treatment of oral cancer. Arch Otolaryngol Head Neck Surg 123: 1298-1302
37. Sun XF, Zhang H (2007) NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 22: 1387-1398
38. Tran HM, Shi G, Li G, Carney JP, O'Malley Jr BW, Li D (2004) Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer. Otolaryngol Head Neck Surg 131: 477-484
39. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, Beckmann G, Seemanová E, Cooper PR, Nowak NJ, Stumm M, Weemaes CM, Gatti RA, Wilson RK, Digweed M, Rosenthal A, Sperling K, Concannon P, Reis A (1998) Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93: 467-476
40. Wakulich C, Jackson-Boeters L, Daley TD, Wysocki GP (2002) Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93: 573-579
41. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180
42. Williams RS, Williams JS, Tainer JA (2007) Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol 85: 509-520
43. Yao X, Yoshioka Y, Morishige T (2010) Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration. Biol Pharm Bull 33: 1073-1076